Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Jardiance (empagliflozin) for the Treatment of Type 2 Diabetes

Drug Name (Brand / Generic)

Jardiance® (empagliflozin)

Developed by

Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company

Product Description

Sodium glucose co-transporter-2 (SGLT2) inhibitor class

Current Indication

Type 2 diabetes

Market Sector

Diabetes

Development Status

Approved in the US and Europe
Expand
Close
Close
Close

Go Top